Understand low testosterone results, the EAU threshold, relevant symptoms and why separate fasting morning measurements matter in clinical evaluation.
A low testosterone result is a blood test finding below a laboratory's reference interval or a clinical decision threshold. Total testosterone is the measurement used in the European Association of Urology (EAU) guideline's initial evaluation. Late-onset hypogonadism is a clinical diagnosis that requires compatible symptoms or signs alongside consistently low testosterone measurements.
This article is for informational purposes and is not medical advice. It does not diagnose testosterone deficiency or recommend treatment. Decisions about testing and follow-up belong with a qualified clinician who can assess the individual's circumstances.
The EAU identifies 12 nmol/L (3.5 ng/mL) as a threshold used in diagnosing late-onset hypogonadism. It applies that threshold alongside symptoms and the clinical profile. It also calls for low morning testosterone on at least two occasions rather than relying on an isolated result.
A reference interval and a diagnostic threshold serve related but different purposes. The interval provides a comparison for the laboratory result. The threshold helps guide clinical evaluation within a particular guideline.
Keep these three parts of interpretation separate:
The EAU threshold is a lower decision point, not a complete normal interval with an upper limit. The guideline also notes limitations in commercial immunoassay reference ranges related to reference populations and conditions before analysis. Its cutoff should therefore not become a universal self-diagnosis rule.
Biologically, the question is whether testosterone remains low under appropriate testing conditions. Clinically, the question is whether that finding fits the man's symptoms and signs. Crossing a numerical boundary addresses only part of that assessment.
Our explanation of reading reference intervals in clinical context provides more detail on that distinction.
The EAU says free-testosterone evaluation may improve diagnostic accuracy in some symptomatic men. This is particularly relevant when conditions affecting sex hormone-binding globulin (SHBG) are present. It recommends measuring SHBG and calculating free testosterone when indicated.
That creates a focused question for the clinician: does the total testosterone result provide enough information in this clinical setting? Additional testing should address that question rather than simply produce a longer list of hormone values.
The guideline also recommends measuring luteinising hormone (LH) and follicle-stimulating hormone (FSH) to help distinguish types of hypogonadism. These are clinician-directed follow-up measurements. They complement the assessment of symptoms and repeated testosterone results.
For background on the terminology, see how total testosterone and free testosterone fit together.
The EAU distinguishes symptoms by how specifically they point toward low testosterone. Among the more specific symptoms in adult men are:
Decreased energy and reduced physical strength are less specific. They still belong in a clinical discussion, but they provide less specific evidence for testosterone deficiency.
Even the more specific sexual symptoms are not exclusive to hypogonadism. Their presence needs interpretation alongside the broader clinical picture. A symptom is therefore something to assess rather than proof of a hormone disorder.
Useful descriptions go beyond naming a symptom. The research-supported preparation approach is to note when it began and how often it occurs. Whether it is changing and how it affects daily life also help organize the discussion.
For example, a record of changing sexual desire gives the clinician something more concrete to review than a general concern about feeling different. The record remains a description of experience rather than a self-assigned diagnosis. Our guide to connecting symptoms with hormone measurements explains that distinction further.
No. In September 2026, the Endocrine Society stated that evidence was insufficient to support population-level screening for hypogonadism in asymptomatic men. Evaluating a person with relevant symptoms or signs is a different question from routinely screening men without them.
For a patient preparing for an appointment, the useful starting point is the concern that prompted testing. That keeps the conversation focused on a clinical question rather than on obtaining a number in isolation.
The EAU identifies several physiological and sampling factors that matter when interpreting testosterone. Some concern when blood is collected. Others concern the person's health or the circumstances surrounding the test.
These factors are reasons to document the testing circumstances. They are not reasons to dismiss an abnormal result without review. The purpose is to make the measurement interpretable alongside the clinical picture.
The following checklist translates the EAU recommendations into discussion points. It is preparation for clinician-led testing rather than an individual testing prescription.
The useful endpoint is not merely obtaining a second number. It is a review in which repeated measurements and symptoms can be considered together. If the reports differ, the collection record gives the clinician specific circumstances to examine during that discussion.
For more background before an appointment, read about preparing for a testosterone measurement. Keep the preparation focused on making the test interpretable rather than trying to influence its outcome.
“Do my symptoms fit testosterone deficiency? Were both measurements taken under appropriate conditions? Would SHBG and calculated free testosterone or LH and FSH help clarify my results?”
Low testosterone evaluation is led by a clinician; Testostra gives men educational context for the hormone measurements involved. Its explanations of total testosterone and free testosterone alongside SHBG address biomarker confusion, helping readers understand the terms behind a laboratory report while keeping general education separate from personal diagnosis and treatment decisions.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra